Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 215 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Valproic Acid (VPA) Clear all

Conditions: Bipolar I Disorder
Interventions: Divalproex Sodium (Depakote ER); Drug
Lead sponsor: Abbott; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 29
States / cities: San Diego, California • San Marcos, California • Altamonte Springs, Florida + 25 more

Conditions: Autism, Developmental Delay, Birth Defects
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 36 Months to 83 Months
Enrollment: 298 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Bipolar Disorder
Interventions: Divalproex Sodium ER, Placebo; Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 16 Years to 65 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Schizophrenia, Bipolar Disorder, Psychotic Disorders
Interventions: divalproex sodium ER/paliperidone ER; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 3
States / cities: Kissimmee, Florida • Austin, Texas • Portsmount, Virginia

Conditions: Migraine in Children
Interventions: Valproic Acid (VPA), Dihydroergotamine (DHE); Drug
Lead sponsor: Kimberly S Jones; Other
Eligibility: 10 Years to 18 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: HIV Infections
Interventions: Valproic acid, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Amblyopia, Amblyopia Unilateral, Amblyopia, Anisometropic, Amblyopia Strabismic
Interventions: Valproate, Placebo, Patch; Drug · Behavioral
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 8 Years to 17 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer
Interventions: VPA FEC100; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Divalproex Sodium Extended-Release Tablets, placebo; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Bipolar I Disorder
Interventions: Bifeprunox; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Brain Injuries, Acute, Brain Injuries, Traumatic, Brain Ischemia, Brain Hypoxia, Hypoxia-Ischemia, Brain, Heart Arrest, Stroke, Intracranial Hemorrhages, Coma, Persistent Vegetative State
Interventions: Phenobarbital Sodium Injection, Levetiracetam, Lacosamide Injectable Product, Valproate Sodium, Fosphenytoin; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Months to 70 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Dementia
Interventions: Depakote; Drug
Lead sponsor: Hearthstone Alzheimer Care; Industry
Eligibility: 60 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Hopkinton, Massachusetts

Conditions: Bipolar Disorder
Interventions: Placebo, Ziprasidone; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 680 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 66
States / cities: Dothan, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 51 more

Conditions: Alcoholism, Alcohol Related Disorders, Mood Disorders
Interventions: divalproex sodium extended release; Drug
Lead sponsor: Seattle Institute for Biomedical and Clinical Research; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: High Grade Sarcoma
Interventions: Valproic Acid; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Bipolar Disorder
Interventions: Valproic Acid; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Major Depressive Disorder, Bipolar Disorder
Interventions: chronobiological augmentation, sertraline, lithium, one night of sleep deprivation and two FDG PET scans; Other · Drug · Radiation
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years to 75 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2011
U.S. locations: 2
States / cities: Irvine, California • La Jolla, California

Conditions: Glial Cell Tumors, Malignant Gliomas, Glioblastoma Multiforme, Anaplastic Astrocytoma, Gliomatosis Cerebri, Gliosarcoma, Brainstem Glioma, Diffuse Intrinsic Pontine Glioma
Interventions: Valproic acid, Bevacizumab, Radiation therapy; Drug · Radiation
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 3 Years to 21 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 6
States / cities: Oklahoma City, Oklahoma • Dallas, Texas • Fort Worth, Texas + 2 more

Conditions: Prostate Cancer
Interventions: valproic acid, standard of care follow-up; Drug · Other
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 85 Years · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Bipolar Disorder
Interventions: Lithium Carbonate, Lamotrigine, Valproic Acid, Oxcarbazepine, Carbamazepine, Ziprasidone, Risperidone, Quetiapine, Olanzapine, Aripiprazole, Fluoxetine / Olanzapine, Haloperidol, Perphenazine, Clozapine, Asenapine, Lurasidone, Paliperidone, Mirtazapine, Bupropion, Desvenlafaxine, Duloxetine, Venlafaxine, Citalopram, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, Vilazodone, Doxepin; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: Not listed
Enrollment: 1,037,352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: HIV Infections
Interventions: Raltegravir; valproic acid; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Bipolar Disorder
Interventions: Lithium, Valproic acid; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Bipolar Disorder Type I With Mania
Interventions: KarXT, Lithium, Valproate, Lamotrigine; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 61
States / cities: Glendale, Arizona • Scottsdale, Arizona • Tucson, Arizona + 49 more

Conditions: Myelodysplastic Syndrome, Acute Myelogenous Leukemia
Interventions: Decitabine, Valproic Acid; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

A Study for the Treatment of Mania Associated With Bipolar I Disorder in Children and Adolescents

Developmental Delay in Children Exposed During Pregnancy to Either Lamotrigine,Sodium Valproate, or Carbamazepine

Double-blind, Placebo-Controlled Divalproex Sodium ER in Bipolar I or Bipolar II Depression

A Drug Interaction Study of Valproic Acid and Paliperidone Extended-Release (ER) in Patients With Schizophrenia, Bipolar I Disorder, or Schizoaffective Disorder

Valproic Acid and Dihydroergotamine as Abortive Therapy in Pediatric Migraine

The Effects of Valproic Acid on Zidovudine Glucuronidation and Pharmacokinetics in HIV-Infected Patients.

Valproate for the Treatment of Residual Amblyopia

Valproic Acid in Combination With FEC100 for Primary Therapy in Patients With Breast Cancer

Does The Addition Of Divalproex Sodium ER To An Atypical Antipsychotic Drug (APD) Improve Cognition And Psychopathology In Outpatients With Schizophrenia (SCH) Or Schizoaffective Disorder (SAD)?

PK Effects of Bifeprunox & Valproate in Bipolar I

Antiseizure Medication in Seizure Networks at Early Acute Brain Injury

Study of Depakote for Behavioral and Psychological Symptoms in Dementia

3-week Study to Evaluate Efficacy and Safety of Ziprasidone With Either Lithium or Divalproex in Acutely Manic Subjects

Placebo Controlled Trial of Depakote ER in Alcohol Dependent Patients With Mood and/or Anxiety Symptoms

Adjuvant Valproate for High Grade Sarcomas

Bipolar Disorder in Late Life

The Role of Dopamine Metabolism in the Antidepressant Effects of Sleep Deprivation and Sertraline in Depressed Patients

Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma

Valproic Acid in Treating Patients With Progressive, Non-Metastatic Prostate Cancer

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

MK-0518 Intensification And HDAC Inhibition In Depletion Of Resting CD4+ T Cell HIV Infection

Effectiveness of Lithium and Valproate in Treating High-Risk Bipolar Disorder

A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)

Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)